R. Eniafe

发表

and acute and chronic myeloid leukemia PRAME-specific peptides in patients with acute lymphoblastic leukemia Ex-vivo characterization of polyclonal memory CD8+ T-cell responses to

K. Rezvani, K. Keyvanfar, A. Barrett, 2013 .

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

K. Rezvani, K. Keyvanfar, A. Barrett, 2009, Blood.

Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.

Marcela R. Uribe, S. Adams, A. Barrett, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57.

D. Follmann, A. Barrett, J. Molldrem, 2003, The hematology journal : the official journal of the European Haematology Association.

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

K. Keyvanfar, S. Adams, A. Barrett, 2009, Blood.

Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator–responder pairs

A. Barrett, N. Hensel, G. Sconocchia, 2003, Bone Marrow Transplantation.

driven graft-versus-leukemia effects - peptide following allogeneic stem cell transplantation and may improve PR1 chronic myeloid leukemia is associated with improved outcome High PR3 or ELA2 expression by CD34+ cells in advanced-phase

K. Rezvani, A. Barrett, S. Mielke, 2013 .

High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.

K. Rezvani, A. Barrett, J. Goldman, 2007, Blood.

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

K. Keyvanfar, A. Barrett, J. Goldman, 2008, Leukemia.

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

K. Rezvani, K. Keyvanfar, A. Barrett, 2008 .

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies

K. Rezvani, A. Barrett, S. Mielke, 2011, Haematologica.

Molecular and flow cytometric characterization of the CD4 and CD8 T‐cell repertoire in patients with myelodysplastic syndrome

D. Follmann, J. Melenhorst, A. Barrett, 2002, British journal of haematology.

Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy

K. Rezvani, R. Childs, S. Mielke, 2012, Cancer Immunology, Immunotherapy.

Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors.

A. Barrett, N. Hensel, A. Schwarer, 2002, Cytotherapy.

Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein

K. Rezvani, K. Keyvanfar, A. Barrett, 2010, Leukemia.

Effect of 5-[125I]iodo-2′-deoxyuridine uptake on the proliferation and pluripotency of human embryonic stem cells

I. Panyutin, R. Neumann, I. Panyutin, 2012, International journal of radiation biology.

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.

K. Keyvanfar, S. Adams, N. Hensel, 2009, Blood.